Results 241 to 250 of about 210,358 (255)

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2020
Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas   +2 more
exaly  

Detection of the 157 micron (1910 GHz) (C II) emission line from the interstellar gas complexes NGC 2024 and M42

, 1980
R. Russell, G. Melnick, G. Gull, M. Harwit   +3 more
semanticscholar   +1 more source

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Lancet, The, 2017
Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg   +2 more
exaly  

Genome destabilization by homologous recombination in the germ line

Nature Reviews Molecular Cell Biology, 2010
Scott Keeney
exaly  

Next-generation characterization of the Cancer Cell Line Encyclopedia

Nature, 2019
Mahmoud Mahdi Ghandi, Franklin W Huang, Gregory V Kryukov   +2 more
exaly  

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Lancet, The, 2013
Dieter Hoelzer
exaly  

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Lancet, The, 2014
Edward B Garon, Oscar Arrieta, Keunchil Park   +2 more
exaly  

On the excitation mechanism of the 21 cm interstellar hydrogen emission line

Physica, 1952
openaire   +1 more source

Anal cancer: Current standards in care and recent changes in practice

Ca-A Cancer Journal for Clinicians, 2015
exaly  

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Lancet, The, 2012
Jeffrey A Cohen, Alasdair J Coles, Douglas L Arnold   +2 more
exaly